<?xml version="1.0" encoding="UTF-8"?>
<p>In October 2016, the technical working group developed and approved the Rwanda viral hepatitis national operational plan. The plan demonstrated priority-setting of key national activities and provided cost estimations for different levels of coverage of screening, diagnosis, and treatment of both hepatitis B and C. The annual cost of a comprehensive national viral hepatitis programme was estimated at US$Â 168.6 million.
 <xref rid="R20" ref-type="bibr">
  <sup>20</sup>
 </xref> Currently, all major private health insurance companies in Rwanda, as well as the military medical insurance, reimburse for the cost of both sofosbuvir with ribavirin and sofosbuvir with ledipasvir. Additionally, the Rwanda social security board, which provides health insurance for public servants, covers 85% of the cost of these drugs for patients. These sources in combination provide coverage to an estimated 7.3% (730/9998) of insured households in Rwanda,
 <xref rid="R23" ref-type="bibr">
  <sup>23</sup>
 </xref> comprising most of the patients started on treatment to date. Reimbursement for HCV viral load testing and hepatitis C treatment by the community-based health insurance scheme, which provides health insurance coverage to at least one member of 97.1% (9708/9998) of households,
 <xref rid="R23" ref-type="bibr">
  <sup>23</sup>
 </xref> is currently under discussion.
</p>
